#United States #Seattle #Magnolia Medical #Steripath #Jason Richey

Magnolia Medical Welcomes Jason Richey as CEO

Seattle, WA - July 29, 2025
In a significant leadership transition, Magnolia Medical Technologies, Inc., the company behind the innovative Steripath® Initial Specimen Diversion Device®, has announced that Jason Richey will serve as the new President and Chief Executive Officer. This appointment, effective from July 14, 2025, marks a pivotal moment for the company as it seeks to enhance its innovative capacity in medical technology.

With over two decades of experience in the realm of medical technology, Richey joins Magnolia Medical at a critical juncture. The company has made substantial strides in implementing a new standard of care related to blood culture accuracy—a vital diagnostic test that has improved patient outcomes significantly. This achievement has been bolstered by the widespread adoption of the Steripath® platform, which claims to have aided nearly 10 million blood cultures performed in U.S. hospitals to monitor bloodstream infections like sepsis.

In his new role, Richey is well-positioned to lead Magnolia Medical into this next phase of growth. He has previously championed the expansion of several high-growth MedTech companies, making his transition into this role a promising development for Magnolia’s trajectory. Greg Bullington, the co-founder and a pivotal figure in Magnolia’s initial commercial success, remarked, "We are excited to welcome Jason to Magnolia Medical. His vast experience makes him the ideal leader to guide our mission forward."

Ron Lowy, Chairman of the Board, echoed this sentiment, emphasizing the Board’s trust in Richey’s abilities to manage the complexities of the industry while capitalizing on Magnolia's groundbreaking technologies. Lowy also expressed gratitude to Bullington for his leadership during a crucial phase of development, particularly concerning the Steripath® technology, which has received recognition as an industry-standard for reliable blood culture collection.

Richey's vision for Magnolia Medical is anchored in a commitment to redefine the benchmarks of diagnostic accuracy, especially relating to sepsis. "The company is at the forefront of improving health outcomes through its clinically proven technologies," he stated. "Supporting patient-centered care is our mission, and I’m eager to collaborate with our talented team to expand our impact and deliver exceptional value."

About Magnolia Medical Technologies

Magnolia Medical specializes in developing and marketing revolutionary blood and bodily fluid collection systems aimed at enhancing diagnostic accuracy. Known for pioneering the Initial Specimen Diversion Technique® (ISDT®) and the Initial Specimen Diversion Device® (ISDD®), the company has built a formidable intellectual property portfolio with over 200 patents and more than 50 active patent applications. Their innovations are critical in reducing contamination in blood cultures, which is vital for effective sepsis diagnosis and treatment.

As Magnolia Medical navigates this exciting new era under Richey's leadership, industry observers and stakeholders alike are keenly interested in how these developments will influence the medical tech landscape and enhance patient care in the coming years.

To learn more about Magnolia Medical Technologies, visit www.magnolia-medical.com.